DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Eczema; Allergy Symptoms; Psoriasis; Itch

Intervention: Alclometasone dipropionate cream (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline


This is a multi-center, open-label study to evaluate whether participants follow the duration of use instructions for short-term use of alclometasone dipropionate in a population of participants with itchy skin conditions who would use OTC treatments for relief. The study population will be composed of two different cohorts: chronic condition sufferers (eczema or psoriasis) and participants who suffer from occasional itchy skin experiences (such as poison ivy, oak, sumac, insect bites, or skin irritations due to jewelry, cosmetics, detergents, or soaps) where an anti-itch medication would be used.

Clinical Details

Official title: A Mult-Center, Open-Label Study to Evaluate Product Duration of Use Experience With Aclometasone Diproprionate Cream

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Number of Participants With Incorrect Duration of Use of the Medication

Secondary outcome:

Number of Times Per Day Participants Used the Product

Number of Days of Use

Detailed description: Approximately 313 participants who are currently suffering from an itchy skin condition caused by eczema or psoriasis or any occasional itchy skin experiences will be enrolled into the study to get 250 participants who complete the study (at least 100 to each of the cohorts). After evaluation of the study criteria, the site staff will dispense product and a diary card to the subject to use over the next 14 days. At the end of the 14 days, each participant will come to the research site to return the remaining product and undergo the study termination interview with the Concentrics nurse via telephone. The study will be conducted in approximately 15 research sites located throughout the United States (US).


Minimum age: 12 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Age: At least 12 years of age.

- Condition: Currently experiencing itch associated with one of the following skin


- psoriasis or eczema,

- minor skin conditions such as those caused by poison ivy, oak, or sumac, insect

bites, or use of cosmetics, soaps, detergents, or jewelry.

- Compliance: Subject or subject's parent or legal guardian understands and is willing,

able and likely to comply with all study procedures and restrictions.

- Consent: Subject or subject's parent or legal guardian demonstrates ability to read

and understand English and is willing to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form (and assent as appropriate). Exclusion Criteria:

- Pregnancy: Women who are known to be pregnant (as self-reported) or who are intending

to become pregnant over the duration of the study. Women of childbearing potential will be allowed to participate in the study so long as they are practicing a reliable method of contraception (e. g. hormonal birth control such as pill, patch, implant or injection; intrauterine device, double barrier methods, tubal ligation, vasectomized spouse or abstinence).

- Corticosteroid Use: Subject has used a corticosteroid treatment within two weeks of

the screening visit at the start of the study.

- Breast-feeding: Women who are breastfeeding.

- Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to

alclometasone cream (or closely related compounds), or any of their stated ingredients.

- Participation in another clinical study or receipt of an investigational drug within

30 days of the screening visit at the start of the study.

Locations and Contacts

Additional Information

Starting date: September 2006
Last updated: August 28, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017